Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 13/20 | 0.61 |
| ▸ | DRD3 | P35462 | 12/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.61 |
| ▸ | HTR2A | P28223 | 4/20 | 0.59 |
| ▸ | HTR1A | P08908 | 3/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | DRD5 | P21918 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21802147 | 0.89 | HTR7 (0.66) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL21802157 | 0.87 | LMNA (0.53) | TRPV1DRD2DRD3ADRA1AHTR2A | |
| SCHEMBL21802020 | 0.84 | DRD3 (0.55) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL21802141 | 0.84 | HTR7 (0.65) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL21802095 | 0.82 | LMNA (0.67) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL21802149 | 0.82 | DRD2 (0.60) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL21802148 | 0.81 | DRD3 (0.59) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL21802154 | 0.81 | DRD2 (0.67) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL21802018 | 0.80 | LMNA (0.59) | DRD2DRD3ADRA1AHTR2AHTR1A | |
| SCHEMBL21802155 | 0.80 | DRD2 (0.75) | DRD2DRD3ADRA1AHTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319659-B2 | Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof | SHENZHEN LINGLAN BIO-PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-06-03 | — | — | US | claimed |
| US-20200087264-A1 | NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | Shenzhen City Linglan Bio-Pharmaceutical Technology Co., Ltd (CN) | 2020-03-19 | — | — | US | claimed |
| US-12319659-B2 | Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof | SHENZHEN LINGLAN BIO-PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-06-03 | — | — | US | disclosed |
| US-20200087264-A1 | NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | Shenzhen City Linglan Bio-Pharmaceutical Technology Co., Ltd (CN) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087264-A1 | NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | DRD3, DRD2, PRLHR | TRPV1 891/4885DRD2 2/4885DRD3 1/4885 |
| US-12319659-B2 | Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof | DRD3, DRD2, PRLHR | TRPV1 794/4885DRD2 2/4885DRD3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.